Green Cross first NDA approval for anticancer drug from US FDA

Green Cross Corporation said on July 7 it received the first new drug approval (NDA) from US Food and Drug Administation for greenstatin, an investigational anticancer drug that inhibits the formation of new blood vessels in tumors.

Company officials said that greenstatin, co-developed between Green Cross Corp. and Mogam Biotechnology Research Institute, inhibits the growth of metastatic tum...